Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

31.7%

13 terminated/withdrawn out of 41 trials

Success Rate

56.7%

-29.8% vs industry average

Late-Stage Pipeline

34%

14 trials in Phase 3/4

Results Transparency

47%

8 of 17 completed trials have results

Key Signals

6 recruiting8 with results9 withdrawn

Enrollment Performance

Analytics

Phase 2

8(29.6%)

Phase 3

7(25.9%)

Phase 4

7(25.9%)

N/A

3(11.1%)

Phase 1

2(7.4%)

27Total

Phase 2(8)

Phase 3(7)

Phase 4(7)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (41)

Showing 20 of 41 trials

NCT05243797Phase 3Recruiting

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Role: collaborator

NCT06353022Phase 2Active Not Recruiting

Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

Role: collaborator

NCT04592237Phase 2Active Not Recruiting

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

Role: collaborator

NCT04181203Phase 3Active Not Recruiting

Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy

Role: collaborator

NCT04131309Phase 2Completed

A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

Role: collaborator

NCT06477783Recruiting

Study on the Clinical Efficacy of Teclistamab

Role: collaborator

NCT00825929Recruiting

Pharmacokinetics of Antiretroviral Agents in HIV-infected Pregnant Women.

Role: collaborator

NCT06505369Phase 2Recruiting

Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

Role: collaborator

NCT03141671Phase 2Active Not Recruiting

Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)

Role: collaborator

NCT04121208Phase 1Terminated

MIcroglial Colony Stimulating Factor-1 Receptor (CSF1R) in Alzheimer's Disease

Role: collaborator

NCT06189833Phase 2Recruiting

Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

Role: collaborator

NCT03899077Phase 2Recruiting

Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP

Role: collaborator

NCT03017872Phase 4Unknown

Dolutegravir and Darunavir Evaluation in Adults Failing Therapy

Role: collaborator

NCT01805557Phase 2Completed

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Role: collaborator

NCT00204347Phase 4Completed

Effective Measurement of Risperidone Treatment Outcome for Persons With Borderline Personality Disorder

Role: collaborator

NCT03394196Not ApplicableTerminated

RESIST-2: 2nd-line ART for HIV-2 Infection

Role: collaborator

NCT04183738Phase 4Withdrawn

Inflammation and Co-Infections in D²EFT

Role: collaborator

NCT02155101Phase 3Completed

Efficacy and Safety Study of Darunavir for the Treatment of HIV/AIDS